Peer Learning and Networking Webinar Series
The NCI SBIR Peer Learning and Networking (PLAN) webinar series provides an interactive forum for SBIR/STTR applicants and awardees to hear best practices from SBIR standout companies that have achieved success towards product development and technological commercialization. Each participating company shares expertise on a specific webinar topic while identifying networking resources that can help others on their journey from lab to market.
This PLAN webinar featured discussions with Lu Alleruzzo, CEO of Immunophotonics, and David Anderson, CSO of Immunophotonics, on perspectives on launching and growing biotech startups. Immunophotonics is a clinical-stage biotech company backed by $40M in funding that is developing a novel interventional immuno-oncology product.
Lu Alleruzzo, M.B.A.
Lu Alleruzzo, M.B.A. is a co-founder and the CEO of Immunophotonics. He received a bachelor’s degree in bioengineering and an MBA with a management emphasis from the University of Missouri–Columbia. He is presently an Entrepreneur in Residence for BioGenerator in addition to serving on the board for a commercial enterprise that generates $15M in annual revenue. Prior to employment at Cerner as well as HP and World Wide Technologies, Mr. Alleruzzo developed a surgical training device and conducted research at the Dalton Cardiovascular Research Center.
David Anderson, Ph.D.
David Anderson, Ph.D. is the Chief Scientific Officer of Immunophotonics. He received his Ph.D. in Immunology and Microbiology at the University of Missouri-Columbia School of Medicine and completed a postdoctoral fellowship in Cellular and Molecular Immunology at the University of Colorado Anschutz Medical Campus. Dr. Anderson has held academic positions at the University of Colorado Health Sciences Center and The Scripps Research Institution. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs. Dr. Anderson has refereed articles for peer-reviewed journals and has an outstanding record of scientific publications and presentations (35 peer-reviewed publications and over 50 presentations/abstracts), and has received several research awards and 10 patents for his innovative research. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation, Cypress Bioscience, Roche, and Nalo Therapeutics (Samsara BioCapital).
Previous PLAN Webinars
To access content from previous PLAN series, click on the link below:
If you have topic suggestions for the PLAN series, please email us at ncisbir@mail.nih.gov.